Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression
1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of...
Read More
Oncology
Darolutamide with chemotherapy and androgen-deprivation therapy improves overall survival in metastatic hormone-sensitive prostate cancer
1. Overall survival was significantly longer in patients taking darolutamide in tandem with...
Read More
Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer
1. Longer progression-free survival was found in patients taking trastuzumab deruxtecan compared...
Read More
Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer
1. Patients with hormone-sensitive prostate cancer receiving darolutamide, an androgen-receptor...
Read More
Religious attendance may be correlated with cancer screening utilization
1. This study found there was a positive association between religious attendance and cancer...
Read More
Examining Age Disparity in Clinical Trial Understanding
“Older adults with cancer are underrepresented in clinical trials, despite comprising the majority...
Read More
Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma
1. Treatment with pembrolizumab yielded a best overall response rate of 71%. 2. Adverse events...
Read More
Ribociclib in addition to letrozole increases overall survival compared to letrozole alone
1. Overall survival was longer in the group receiving ribociclib with letrozole as compared with...
Read More
Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma
1. The median progression-free survival was 7.4 months in the rucaparib group and 5.7 months in...
Read More
Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer
1. Ribociclib plus letrozole provides significant overall survival benefit as compared to...
Read More
Breast cancer overdiagnosis rates not as high as estimated previously
1. About 1 in 7 cases of screen-detected cancer is overdiagnosed in the US population. 2. The rate...
Read More
Postoperative treatment without radioiodine has noninferior outcomes following thyroidectomy
1. Patients with low-risk thyroid cancer undergoing thyroidectomy, who did not receive radioiodine...
Read More
Non-alcoholic fatty liver disease-related hepatocellular carcinoma (HCC) differ clinically compared to HCC due to other causes
1. Patients with NAFLD-related HCC have longer disease-free survival compared to those with HCC...
Read More
Hepatocellular Carcinoma: The Viral Hepatitis Pathways
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and incidence...
Read More
Pertuzumab has clinical benefits in metastatic breast cancer but is not cost-effective
1. The incremental cost-effectiveness ratio of the pertuzumab group was $436,679 per QALY gained....
Read More
Biosimilar HD201 has equivalent efficacy to trastuzumab in the treatment of ERBB2-positive (HER2) breast cancer
1. Total pathological complete response was not significantly different between trastuzumab and...
Read More
Liver Cancer: Support for the 3rd Leading Cancer-Related Cause of Death
Liver cancer is the third-highest cause of cancer-related deaths worldwide, and incidence of...
Read More
Cancer-Associated Thrombosis: A Look at Racial Disparities
When compared with the general population, patients with cancer-associated thrombosis (CAT) have...
Read More
Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: A Nomogram Predicting Overall Survival Benefit
For a study, the researchers sought to create and evaluate a nomogram that could predict overall...
Read More
Compared With Younger Patients, Octogenarians Have a Higher Quality Of Life After Lung Resection
For a study, the researchers sought to compare patients aged less than 80 to patients aged more...
Read More